Skip to main content
Canna~Fangled Abstracts

Efficacy of combined therapy with fish oil and phytocannabinoids in murine intestinal inflammation

By September 30, 2020October 1st, 2020No Comments
. 2020 Sep 30.

doi: 10.1002/ptr.6831.

Online ahead of print.
Ester Pagano 1 2, Fabio A Iannotti 2 3, Fabiana Piscitelli 2 3, Barbara Romano 1 2, Giuseppe Lucariello 1, Tommaso Venneri 1 4, Vincenzo Di Marzo 2 3 4, Angelo A Izzo 1 2, Francesca Borrelli 1 2
Affiliations

Abstract

Fish oil (FO) and phytocannabinoids have received considerable attention for their intestinal anti-inflammatory effects. We investigated whether the combination of FO with cannabigerol (CBG) and cannabidiol (CBD) or a combination of all three treatments results in a more pronounced intestinal antiinflammatory action compared to the effects achieved separately. Colitis was induced in mice by 2,4-dinitrobenzenesulfonic acid (DNBS). CBD and CBG levels were detected and quantified by liquid chromatography coupled with time of flight mass spectrometry and ion trap mass spectrometry (LC-MS-IT-TOF). Endocannabinoids and related mediators were assessed by LC-MS. DNBS increased colon weight/colon length ratio, myeloperoxidase activity, interleukin-1β, and intestinal permeability. CBG, but not CBD, given by oral gavage, ameliorated DNBS-induced colonic inflammation. FO pretreatment (at the inactive dose) increased the antiinflammatory action of CBG and rendered oral CBD effective while reducing endocannabinoid levels. Furthermore, the combination of FO, CBD, and a per se inactive dose of CBG resulted in intestinal anti-inflammatory effects. Finally, FO did not alter phytocannabinoid levels in the serum and in the colon. By highlighting the apparent additivity between phytocannabinoids and FO, our preclinical data support a novel strategy of combining these substances for the potential development of a treatment of inflammatory bowel disease.

 

Keywords: cannabidiol, cannabigerol, fish oil, inflammatory bowel disease, phytocannabinoids

References

REFERENCES

    1. Batetta, B., Griinari, M., Carta, G., Murru, E., Ligresti, A., Cordeddu, L., … Banni, S. (2009). Endocannabinoids may mediate the ability of (n-3) fatty acids to reduce ectopic fat and inflammatory mediators in obese Zucker rats. The Journal of Nutrition, 139(8), 1495-1501. https://doi.org/10.3945/jn.109.104844
    1. Belluzzi, A., Boschi, S., Brignola, C., Munarini, A., Cariani, G., & Miglio, F. (2000). Polyunsaturated fatty acids and inflammatory bowel disease. The American Journal of Clinical Nutrition, 71(1 Suppl), 339S-342S. https://doi.org/10.1093/ajcn/71.1.339s
    1. Bisogno, T., Hanus, L., De Petrocellis, L., Tchilibon, S., Ponde, D. E., Brandi, I., … Di Marzo, V. (2001). Molecular targets for cannabidiol and its synthetic analogues: Effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. British Journal of Pharmacology, 134(4), 845-852. https://doi.org/10.1038/sj.bjp.0704327
    1. Borrelli, F., Aviello, G., Romano, B., Orlando, P., Capasso, R., Maiello, F., … Izzo, A. A. (2009). Cannabidiol, a safe and non-psychotropic ingredient of the marijuana plant Cannabis sativa, is protective in a murine model of colitis. Journal of Molecular Medicine, 87(11), 1111-1121. https://doi.org/10.1007/s00109-009-0512-x
    1. Borrelli, F., Fasolino, I., Romano, B., Capasso, R., Maiello, F., Coppola, D., … Izzo, A. A. (2013). Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease. Biochemical Pharmacology, 85(9), 1306-1316. https://doi.org/10.1016/j.bcp.2013.01.017

Grant support

Leave a Reply